Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Language
Publication year range
1.
J Med Virol ; 85(4): 597-601, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23359331

ABSTRACT

Screening hepatitis B virus (HBV) surface antigen (HBsAg) and HBV core antibody (anti-HBc) is recommended prior to cytotoxic or immunosuppressive therapy. This case describes an anti-HBc negative, DNA positive occult HBV infection in a 71-year-old Caucasian male following rituximab-based treatment for follicular lymphoma. Pre-screening serology indicated negative HBsAg and anti-HBc. However, following sequential treatment cycles the patient developed weak HBsAg with a low HBV DNA load (<1,000 IU/ml), but remained anti-HBc negative. The DNA load peaked 5 months later (>1 × 10(6) IU/ml) and he was subsequently treated with Tenofovir. Currently the patient remains anti-HBc negative, and is anti-HBe negative, anti-HBs negative, HBeAg positive. No clinical or biochemical evidence of hepatitis has occurred. Sequencing and phylogenetic analysis identified the HBV genosubtype as D4, most probably acquired some years ago during a stay in Papua New Guinea, in spite of prior hepatitis B vaccination. Four amino acid substitutions were detected within the HBsAg loop yet none in the core protein. This case questions the dependability of anti-HBc testing and highlights the role of HBV DNA testing prior to and throughout cytotoxic or immunosuppressive regimes. As this case exemplifies, vaccination protects against clinical infection but may not exclude seronegative occult infection with the possibility of reactivation.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antibodies, Monoclonal, Murine-Derived/adverse effects , Hepatitis B/chemically induced , Immunologic Factors/administration & dosage , Immunologic Factors/adverse effects , Lymphoma/drug therapy , Virus Activation/drug effects , Adenine/administration & dosage , Adenine/analogs & derivatives , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Antiviral Agents/administration & dosage , DNA, Viral/blood , DNA, Viral/chemistry , DNA, Viral/genetics , Genotype , Hepatitis B/drug therapy , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis B virus/isolation & purification , Humans , Male , Organophosphonates/administration & dosage , Papua New Guinea , Phylogeny , Rituximab , Sequence Analysis, DNA , Tenofovir , Viral Load
3.
Dig Dis ; 28(1): 116-25, 2010.
Article in English | MEDLINE | ID: mdl-20460899

ABSTRACT

The Taormina Consensus Conference defined 'occult hepatitis B virus (HBV) infection' (OBI) as the 'presence of HBV DNA in the liver of individuals testing HBsAg-negative with currently available assays'. Most occult is the so-called 'window period' after exposure before HBV DNA appears in the blood. We identified two blood donors whose donations tested HBsAg- and HBV DNA-negative, but transmitted HBV. Both subsequently developed HBsAg and acute hepatitis. However, such cases are not considered as true OBI. A true transient OBI remains HBsAg-negative during the entire course. One case of acute OBI showed a peak viremia of 15,000 IU/ml HBV DNA and sub-borderline HBsAg, suggesting a ratio of virions to subviral particles of 1:10, whereas 'normal' cases show at peak viremia a ratio of 1:3,000. Blood donors with OBI may transmit HBV. We studied 5 blood donors with OBI and 55 of their recipients. In 22 recipients, transmission was probable, but they remained healthy. However, in 3 recipients, who were immunosuppressed at the time of transfusion, fatal fulminant hepatitis B developed. The majority of anti-HBc-positive healthy individuals have HBV DNA in the liver which may start replication under severe immunosuppression. Nine such cases are described here. OBI or reactivated HBV infections often lead to selection of HBsAg escape mutations as we could show in 11 of 14 cases. Infection of vaccinated individuals favors development of OBI as we observed in 6 blood donors. HB vaccination may solve the problem of overt HBV infection but may favor OBI.


Subject(s)
Hepatitis B/diagnosis , Acute Disease , Blood Donors , DNA, Viral/analysis , Hepatitis B/prevention & control , Hepatitis B/transmission , Hepatitis B/virology , Hepatitis B Surface Antigens/blood , Hepatitis B virus/genetics , Hepatitis B virus/isolation & purification , Hepatitis B virus/physiology , Humans , Liver/virology , Vaccination , Viremia , Virion/isolation & purification , Virus Activation
4.
J Clin Virol ; 47(3): 238-42, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20117963

ABSTRACT

BACKGROUND: Standard preparations for HBsAg are required for quality control of test kits and clinical studies on HBsAg quantitation. WHO provides purified heat inactivated HBsAg diluted in negative defribinated plasma as 2nd International Standard (IS) for quality control of tests. OBJECTIVE: Study of possible alterations of antigenicity, protein composition, size and density of the heat inactivated source material (SM) for the 2nd IS. STUDY DESIGN: Native HBsAg and SM were examined by quantitative immune electrophoresis (QIE), SDS-PAGE, ultracentrifugation and gel chromatography. HBV DNA was sequenced and the HBsAg geno/subtype derived. RESULTS: The SM contained 97,600 International Units HBsAg/ml in QIE which agreed very well with the previous evaluations by WHO using 10 different assays. In SDS-PAGE, SM showed on a strong background the small HBs proteins but no preS proteins. SM had a more heterogeneous density than native HBsAg and contained particle aggregates. The HBsAg geno/subtype of SM was A2/adw2. CONCLUSIONS: The IS has very good HBs antigenicity, but it lacks the preS domains, has modified HBs proteins and is partially aggregated. While it has been proven very useful for quality control of tests, certain inconsistencies due to the altered structure of its HBsAg cannot be excluded.


Subject(s)
Hepatitis B Surface Antigens/chemistry , Hepatitis B Surface Antigens/immunology , Hepatitis B/diagnosis , Immunoassay/standards , Virology/methods , Animals , Chromatography, Gel , Electrophoresis, Polyacrylamide Gel , Humans , Reference Standards , Ultracentrifugation
5.
Transfusion ; 49(8): 1621-9, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19413737

ABSTRACT

BACKGROUND: Screening of blood donors for viral nucleic acids has recently been introduced in several countries. With the use of transcription-mediated amplification, a blood donor was detected who had 90,000 copies of hepatitis B virus (HBV) DNA/mL but no hepatitis B surface antigen (HBsAg) or antibody to hepatitis B core antigen (anti-HBc). One month later, anti-HBc and hepatitis B surface antibody (anti-HBs) appeared; HBV DNA disappeared after 2 months. This study asked why HBsAg was undetectable in this rare case of transient occult HBV infection. STUDY DESIGN AND METHODS: The HBV DNA in the first sample was cloned and sequenced to identify mutations. The physical nature of the virus was examined by polyethylene glycol precipitation, DNase digestion, density gradient centrifugation, and immunoprecipitation. RESULTS: Several mutations were found all over the genome, but the HBs antigen loop was unchanged. A stop mutation in the precore region led to loss of hepatitis B e antigen (HBeAg) expression. No HBV DNA­containing immune complexes were present. The plasma did not contain nonencapsidated HBV DNA that could explain the absence of HBsAg. The virus was immune precipitated by antibodies against HBsAg or preS1 antigen. The ratio of HBV to HBsAg subviral particles was estimated to be 1 in less than 20 whereas in overt cases the ratio is 1 in more than 1000. CONCLUSION: The acute resolving occult HBV infection was caused by an HBeAg-negative variant, which otherwise was almost normal. The negative HBsAg result was probably due to an unusually low production of surplus HBsAg. The absence of the viral immunomodulator HBeAg and the early appearance of anti-HBs suggested a rapid noncytolytic HBsAg-specific T-cell response leading to low expression of HBsAg.


Subject(s)
Blood Donors , DNA, Viral/blood , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis B virus , Hepatitis B , Viremia , Donor Selection , Female , Hepatitis B/blood , Hepatitis B/epidemiology , Humans , Male , Nucleic Acid Amplification Techniques/methods , Time Factors
6.
J Clin Virol ; 38(2): 146-8, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17182277

ABSTRACT

BACKGROUND: Reactivation of a hepatitis B virus (HBV) infection after transplantation is associated with a high morbidity and mortality. HBV infections generally result in anti-HBc persisting lifelong. CASE REPORT: A 44-year-old female presented 10 years after allogeneic stem cell transplantation with a chronic hepatitis B. The infection was reactivated from a resolved (anti-HBs and anti-HBc positive) HBV infection acquired some years prior to transplantation. Interestingly, she lost all antibodies to HBV including anti-HBc and is upto now anti-HBc negative. The sequence of the surface and the core gene did not reveal any escape mutations. Thus, the loss of anti-HBc might suggest an immunotolerance of the donor's immune system against HBcAg. CONCLUSION: This data illustrate that an HBV infection might be reactivated despite high anti-HBs levels prior to transplantation. Furthermore, this is the first patient in which a complete loss of anti-HBc could be documented. Moreover, since anti-HBc is often used as a screening marker for HBV it should be kept in mind that anti-HBc negative patients with high viremic HBV infection may occur.


Subject(s)
Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B virus/physiology , Hepatitis B, Chronic/immunology , Stem Cell Transplantation , Adult , Female , Hepatitis B Core Antigens/blood , Hepatitis B Surface Antigens/blood , Hepatitis B virus/growth & development , Hepatitis B virus/immunology , Hepatitis B, Chronic/virology , Humans , Transplantation, Homologous , Virus Activation
7.
J Clin Virol ; 38(1): 83-6, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17134939

ABSTRACT

BACKGROUND: Hepatitis B virus (HBV) often persists after resolution, but its replication is suppressed by antiviral T cells. Immunosuppressive treatment may lead to viral reactivation and severe hepatitis. Early antiviral therapy prevents reactivation but some occult HBV infections are not easily detectable. RESULTS: Here we describe a patient with a progressive non-Hodgkin lymphoma who had probably not been vaccinated against HBV and, before immunosuppression, showed antibodies (anti-HBs) against the viral surface antigen (HBsAg) as the only possible marker of occult HBV infection. Under immunosuppression he developed viremia (>10(8)copies/mL). The virus exhibited three S gene mutations (L109R, C137W, G145R) which led to false negative HBsAg results and diminished binding of vaccine-induced anti-HBs. CONCLUSIONS: Reliable screening and monitoring of severely immunosuppressed patients for HBV should include, in addition to anti-HBc and HBsAg, anti-HBs and sensitive HBV DNA assays. Furthermore, active vaccination or hepatitis B immune globulin may not protect against such mutants.


Subject(s)
Hepatitis B Antibodies/blood , Hepatitis B virus/physiology , Hepatitis B/etiology , Lymphoma, Non-Hodgkin/complications , Adult , False Negative Reactions , Hepatitis B/blood , Hepatitis B/virology , Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/genetics , Hepatitis B Surface Antigens/immunology , Humans , Immunocompromised Host , Lymphoma, Non-Hodgkin/immunology , Male , Mutation , Viremia , Virus Activation
8.
N Engl J Med ; 354(17): 1807-12, 2006 Apr 27.
Article in English | MEDLINE | ID: mdl-16641397

ABSTRACT

The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, Gilead). All three cases involved a rare HBV variant with a valine at position 233 of the reverse-transcriptase domain instead of isoleucine (rtI233V), as in the wild-type virus. This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir in vitro.


Subject(s)
Adenine/analogs & derivatives , Drug Resistance, Viral , Hepatitis B virus/genetics , Hepatitis B, Chronic/drug therapy , Organophosphonates/therapeutic use , RNA-Directed DNA Polymerase/genetics , Reverse Transcriptase Inhibitors/therapeutic use , Adenine/pharmacology , Adenine/therapeutic use , Amino Acid Sequence , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , DNA, Viral/biosynthesis , Drug Resistance, Viral/genetics , Female , Hepatitis B, Chronic/virology , Humans , Lamivudine/pharmacology , Lamivudine/therapeutic use , Male , Middle Aged , Molecular Sequence Data , Mutation , Organophosphonates/pharmacology , Reverse Transcriptase Inhibitors/pharmacology , Tenofovir , Viremia
9.
J Clin Virol ; 27(1): 30-7, 2003 May.
Article in English | MEDLINE | ID: mdl-12727526

ABSTRACT

BACKGROUND: The family of Hepadnaviridae is made up of members infecting birds (genus Avihepadnavirus) or mammals (genus Orthohepadnavirus). Hepatitis B virus (HBV), the hepadnavirus infecting humans, can be divided into the seven genotypes A-G. By definition, genotypes differ by more than 8% at the nucleotide level. However, some genotypes differ by more than 14% from others. OBJECTIVES: The diversity of HBV genotypes necessitates great care in primer design to find primers suitable for routine diagnostic procedures that are highly conserved. Our aim was to find a target sequence on the HBV genome that is highly conserved among all known orthohepadnaviruses, to avoid false-negative polymerase chain reaction (PCR) results due to uncommon variants of HBV. METHODS: Using an alignment of 177 genomes of orthohepadnaviruses from GenBank, we selected a primer pair from a highly conserved region, corresponding to hydrophobic transmembrane domains of the major surface protein of HBV. RESULTS: The primer pair chosen was suitable to amplify genome sequences from HBV and to the genetically most distant woodchuck hepatitis virus in real-time PCR using the LightCycler, Roche. Moreover, the primers were suitable for accurate quantitation of both viral genomes over a range from 100 to 10(10) genomes/ml. CONCLUSION: The described primers are useful for reliable detection and accurate quantitation of all known hepadnaviral genomes and may be used for the search for unknown orthohepadnaviruses.


Subject(s)
DNA Primers , Orthohepadnavirus/classification , Orthohepadnavirus/genetics , Polymerase Chain Reaction/methods , Animals , DNA, Viral/analysis , DNA, Viral/genetics , Genome, Viral , Hepatitis B Virus, Woodchuck/genetics , Hepatitis B virus/genetics , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...